{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:00:41Z","timestamp":1781632841373,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"DOI":"10.1007\/s10554-026-03614-y","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:27:37Z","timestamp":1768786057000},"page":"687-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distribution and prognostic implications of right and left ventricular systolic dysfunction in wild-type transthyretin amyloid cardiomyopathy"],"prefix":"10.1007","volume":"42","author":[{"given":"Ali Hussein Jaber","family":"Mejren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Ladefoged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lehmann Dahl","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor S.","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marish I. F. J.","family":"Oerlemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sie Kronborg","family":"Fensman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads J.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3614_CR1","doi-asserted-by":"publisher","unstructured":"Quarta CC, Kruger JL, Falk RH (2012) Cardiac. Amyloidosis Circulation 126. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.069195","DOI":"10.1161\/CIRCULATIONAHA.111.069195"},{"key":"3614_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.110.010447","volume":"124","author":"RH Falk","year":"2011","unstructured":"Falk RH, Cardiac Amyloidosis (2011) Circulation 124:1079\u20131085. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.010447","journal-title":"Circulation"},{"key":"3614_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2024.10.011","volume-title":"The last decade in cardiac amyloidosis","author":"M Fontana","year":"2025","unstructured":"Fontana M, Ioannou A, Cuddy S, Dorbala S, Masri A, Moon JC et al (2025) The last decade in cardiac amyloidosis. JACC Cardiovasc Imaging https:\/\/doi.org\/10.1016\/j.jcmg.2024.10.011"},{"key":"3614_CR4","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-del Moral FJ, Cobo-Marcos M, Robles C et al (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"3614_CR5","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42:1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"3614_CR6","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s12350-020-02098-0","volume":"27","author":"T Asif","year":"2020","unstructured":"Asif T, Araujo T, Singh V, Malhotra S (2020) High prevalence of heart failure with reduced ejection fraction in patients with transthyretin cardiac amyloidosis. J Nuclear Cardiol 27:1044\u20131046. https:\/\/doi.org\/10.1007\/s12350-020-02098-0","journal-title":"J Nuclear Cardiol"},{"key":"3614_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2418965","author":"A van der Achten","year":"2024","unstructured":"Achten A, Muller SA, Wijk SS, van der Meer MG, van der Harst P, van Tintelen P et al (2024) Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction. Ann Med https:\/\/doi.org\/10.1080\/07853890.2024.2418965","journal-title":"Ann Med"},{"key":"3614_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.0717","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Fine N, Weissman NJ, Castano A, Gundapaneni B, Sultan MB et al (2021) Patients with transthyretin amyloid cardiomyopathy May have preserved, mildly reduced, or reduced ejection fraction. Eur Heart J https:\/\/doi.org\/10.1093\/eurheartj\/ehab724.0717","journal-title":"Eur Heart J"},{"key":"3614_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeac011","author":"M van der Brons","year":"2022","unstructured":"Brons M, Muller SA, Rutten FH, van der Meer MG, Vrancken AFJE, Minnema MC et al (2022) Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. Eur Heart J Open https:\/\/doi.org\/10.1093\/ehjopen\/oeac011","journal-title":"Eur Heart J Open"},{"key":"3614_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40477-023-00789-1","volume":"26","author":"M Tana","year":"2023","unstructured":"Tana M, Tana C, Palmiero G, Mantini C, Coppola MG, Limongelli G et al (2023) Imaging findings of right cardiac amyloidosis: impact on prognosis and clinical course. J Ultrasound 26:605\u2013614. https:\/\/doi.org\/10.1007\/s40477-023-00789-1","journal-title":"J Ultrasound"},{"key":"3614_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799\u20132806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589","journal-title":"Eur Heart J"},{"key":"3614_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 28:1\u201339e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003","journal-title":"J Am Soc Echocardiogr"},{"key":"3614_CR13","doi-asserted-by":"publisher","first-page":"qyaf101","DOI":"10.1093\/EHJIMP\/QYAF101","volume":"3","author":"F Gong","year":"2025","unstructured":"Gong F, Akhter N, Vaitenas I, Wodzinski B, Lancki N, Welty LJ et al (2025) Reliability of left ventricular global longitudinal strain across acquisition and analysis techniques: a prospective comparative study. Eur Heart J Imaging Methods Pract 3:qyaf101. https:\/\/doi.org\/10.1093\/EHJIMP\/QYAF101","journal-title":"Eur Heart J Imaging Methods Pract"},{"key":"3614_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.echo.2016.08.006","volume":"29","author":"AL Crowley","year":"2016","unstructured":"Crowley AL, Yow E, Barnhart HX, Daubert MA, Bigelow R, Sullivan DC et al (2016) Critical review of current approaches for echocardiographic reproducibility and reliability assessment in clinical research. J Am Soc Echocardiogr 29:1144\u20131154e7. https:\/\/doi.org\/10.1016\/j.echo.2016.08.006","journal-title":"J Am Soc Echocardiogr"},{"key":"3614_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/J.MEDINE.2016.02.005","volume":"40","author":"SG Olmos-Temois","year":"2016","unstructured":"Olmos-Temois SG, Santos-Mart\u00ednez LE, \u00c1lvarez-\u00c1lvarez R, Guti\u00e9rrez-Delgado LG, Baranda-Tovar FM (2016) Interobserver agreement on the echocardiographic parameters that estimate right ventricular systolic function in the early postoperative period of cardiac surgery. Med Intensiva (English Edition) 40:491\u2013498. https:\/\/doi.org\/10.1016\/J.MEDINE.2016.02.005","journal-title":"Med Intensiva (English Edition)"},{"key":"3614_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M et al (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006075"},{"key":"3614_CR17","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1262","volume-title":"World heart federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","author":"D de Brito","year":"2023","unstructured":"Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I et al (2023) World heart federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM). Glob Heart https:\/\/doi.org\/10.5334\/gh.1262"},{"key":"3614_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034213","author":"B Ladefoged","year":"2024","unstructured":"Ladefoged B, Pedersen AD, Seefeldt J, Nielsen BRR, Eiskj\u00e6r H, Lichscheidt E et al (2024) Exercise hemodynamics and mitochondrial oxidative capacity in disease stages of Wild-Type transthyretin amyloid cardiomyopathy. J Am Heart Assoc https:\/\/doi.org\/10.1161\/JAHA.124.034213","journal-title":"J Am Heart Assoc"},{"key":"3614_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 29:277\u2013314. https:\/\/doi.org\/10.1016\/j.echo.2016.01.011","journal-title":"J Am Soc Echocardiogr"},{"key":"3614_CR20","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3390\/jcm14030668","volume":"14","author":"A Venkateshvaran","year":"2025","unstructured":"Venkateshvaran A, Edbom F, Arvidsson S, Kovacs A, Lindqvist P (2025) Three-Dimensional echocardiographic assessment of right ventricular global myocardial work and ventricular\u2013Pulmonary coupling in ATTR cardiac amyloidosis. J Clin Med 14:668. https:\/\/doi.org\/10.3390\/jcm14030668","journal-title":"J Clin Med"},{"key":"3614_CR21","doi-asserted-by":"publisher","unstructured":"Schwarting S, Poledniczek M, Metodiev Y, Stolz L, Hofmann E, Hegenbart U et al (2024) RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy. Eur Heart J https:\/\/doi.org\/10.1093\/eurheartj\/ehae666.2076","DOI":"10.1093\/eurheartj\/ehae666.2076"},{"key":"3614_CR22","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","volume":"149","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C et al (2024) Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy. Circulation 149:1157\u20131168. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066524","journal-title":"Circulation"},{"key":"3614_CR23","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M et al (2020) Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J 41:1439\u20131447. https:\/\/doi.org\/10.1093\/eurheartj\/ehz905","journal-title":"Eur Heart J"},{"key":"3614_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G et al (2016) Natural history of Wild-Type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014\u20131020. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"3614_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","volume":"12","author":"DS Knight","year":"2019","unstructured":"Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A et al (2019) Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging 12:823\u2013833. https:\/\/doi.org\/10.1016\/j.jcmg.2018.02.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"3614_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/EJHF.3696;CSUBTYPE:STRING:AHEAD","author":"T Damy","year":"2025","unstructured":"Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M (2025) Long-term efficacy of Tafamidis in patients with transthyretin amyloid cardiomyopathy by National amyloidosis centre stage. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/EJHF.3696;CSUBTYPE:STRING:AHEAD","journal-title":"Eur J Heart Fail"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-026-03614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-026-03614-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-026-03614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:48:06Z","timestamp":1781632086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-026-03614-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1007\/s10554-026-03614-y","relation":{},"ISSN":["1875-8312"],"issn-type":[{"value":"1875-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial disclosure for the authors: AHJM, BL, SKF, and ALDP received financial support (travel and accommodation) from Pfizer to attend AttRISE meeting in Stockholm, Sweden. BL received speaker fees from Pfizer for the same event. The University Medical Center Utrecht, which employs M.I.F.J.O., received consultancy fees from Pfizer, AstraZeneca, Bayern and Alnylam. MJA received advisory board consulting fees and\/or speaker fees from MSD, Johnson and Johnson, AstraZeneca, and Boehringer Ingelheim. SHP received research support from Novo Nordic A\/S; advisory board consulting fees from Pfizer, Bayer, AstraZeneca, and BridgeBio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Regional Research Office of Central Jutland (1-45-70-134-23). The data were originally collected as part of a quality control study registered in the Region of Central Denmark in accordance with Danish law (1-16-02-446-21). As a quality control study, informed consent from participants was not required, and approval from the national ethics committee was not mandated. For the present study, a retrospective analysis was conducted with additional approval from the Region of Central Denmark (1-45-70-134-23), including permission to retrieve supplementary clinical data from patient records. Informed consent from participants was not required. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}